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The last several decades have brought signiﬁcant immu-
nologic advances in the ﬁelds of inﬂammation, infection, and
transplantation tolerance. Heretofore, our understanding of
how complex immune interactions occur has been limited to
static in situ tissue analysis and in vitro dynamic studies
using isolated cells devoid of stromal elements typically
present in vivo. Recent advances in molecular, ﬂow cytom-
etry, and intravital imaging have provided new insight into
the dynamic interactions occurring among a variety of cells
within the bone marrow (BM) and immune systems, ranging
from undifferentiated hematopoietic progenitors to fully
committed effector memory cells, which will likely have
direct clinical and translational implications. In this review
we highlight how the application of these cutting-edge
technologies will sculpt the landscape of the next genera-
tion of immunologic advances.NEW IMAGING
Real-Time Interrogation of Cellular Homing and Tissue
Response Dynamics in the BM and Brain
Dynamic nature of hematopoietic lineage cells
The blood and immune systems are derived from hema-
topoietic stem cells (HSCs), rare multipotent cells with self-
renewing capacity. The BM provides the microenvironment
in which HSCs reside, allowing the development of their
closest progeny, hematopoietic progenitor cells (HPCs).
Together, hematopoietic stem and progenitor cells (HSPCs)
produce, maintain, and regenerate lineage-restricted blood
and immune progenitor cells [1]. HSPC activities within the
BM niche can be modulated through communications with
BM-resident stromal cells and mature immune cells. Along
with their differentiated leukocyte progeny, HSPCs have the
ability to migrate between BM and other tissue sites and to
provide reconstitution after BMT [2]. Thus, understanding
the control of recruitment, migration, and interaction
dynamics of these cells has direct clinical and translational
implications. In this regard, more is known about the
migratory behavior of mature immune cells, whose intrinsicFinancial disclosure: See Acknowledgments on page S50.
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among various tissue compartments has profound effects on
these cells’ overall functional outcome. For instance, effector
cells of the innate immune system are rapidly mobilized
from BM and enter inﬂamed tissues from the blood, whereas
sentinel antigen-presenting cells (APCs), such as dendritic
cells, mobilize from peripheral tissues and transit to local
draining lymph nodes [3]. These orchestrated series of
interactions result in changes in gene expression, alterations
in surface receptor repertoire, and production of effector
molecules to ensure the quality and magnitude of immune
responses against foreign challenges [4].
Intravital microscopy shedding new light
Until a decade ago, evidence for immune cell trafﬁcking
and stem cell homing was largely inferred from static tissue
analysis, as well as in vitro dynamic studies of isolated cells
devoid of stromal elements typically present in vivo [5].
Similarly, early imaging studies were limited to low-
resolution leukocyte behavior in assessable anatomic sites,
such as blood vessels [6]. The development of intravital
2-photon laser scanning microscopy (2P-LSM) overcome
these technical limitations, and 2P-LSM has become a tool of
choice for detailed assessment of in vivo cellular migration
and interactions [7]. To date, data generated with
2P-LSMdwhose advantages include increased visual depth
(>200 mm), high spatial resolution (<1 mm), superb signal-
to-noise ratio, reduced photobleaching, prolonged acquisi-
tion (minutes to hours), and a multiplex dataset (xyzt with
multispectral detection)dhave yielded new perspectives
and insights into how, where, and when immune cells
interact in vivo [8]. More recently, application of 2P-LSM has
enabled detailed, real-time assessment of cellular migration
and interactions within the intact BM cavitydfunctions
critical to the homing and early engraftment of HSPCs [9].
Visualizing the BM niche in situ
Using a combination of confocal and intravital 2P-LSM
imaging methods, Lo Celso et al. [9] tracked individual
hematopoietic cells within the calvarium BM of mice. This
study was designed to examine the relationships between
HSPCs and blood vessels, osteoblasts, and endosteal surfaces
as they home and engraft in irradiated, c-Kit recep-
toredeﬁcient recipient mice. Their analysis showed thaterican Society for Blood and Marrow Transplantation.
Figure 1. Dynamic mobilization of neutrophils in the BM after systemic LPS challenge. LPS (100 ng) was administered i.v. into a LysM-GFPþ//ubiquitin-CFP chimera
mouse during an intravital 2P-LSM imaging session on the calvarium BM cavity. (A) Representative snapshots showing the dynamic nature of neutrophil (green)
mobilization in the BM. Time stamp ¼min:sec relative to LPS administration. (Scale bar: 50 mm.) Vessels are highlighted by TRITC-dextran (red). Note the fenestrated
endothelium (blue-white). (B and C) Two zoomed-in views of (A) at the same 3 time points, showing rapid “swarming” behavior by BM-resident neutrophils (white
arrows) in response to LPS.
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architecture comprising osteoblasts and microvessels.
Furthermore, HSPC subsets localize to distinct BM sub-
locations during differentiation in both a cell-autonomous
and cell-nonautonomous manner. Our laboratory also used
2P-LSM to demonstrate the effect of differential Notch
glycosylation of HSPCs on BM niche occupancy [10]. Mendez-
Ferrer et al. [11] subsequently demonstrated that mesen-
chymal stem cells exhibit a symbiotic relationship with
HSPCs as heterotypic stem cell pairs within a unique BM
niche.
To further advance our understanding of cellular
dynamics in the BM space, we studied one of the most
abundant cellular components in the BM, the poly-
morphonuclear neutrophils (PMNs). We applied 2P-LSM to
the calvarium BM of LysM-eGFPþ/- knockin mice in which
one allele of lysozymeM (an abundant enzyme in developing
andmature PMNs) is replaced by enhanced green ﬂuorescent
protein (eGFP) to facilitate the study of early PMN mobili-
zation in a model of systemic sepsis. As early as 30 minutes
after i.v. injection of lipopolysaccharide (LPS), the BM-
resident PMNs appear to “swarm” and rapidly mobilize
within the BM cavity (Figure 1 and Supplemental Movie 1),
presumably in response to local and systemic signals for
release of PMNs into the general circulation. Using BM
chimeras, we are beginning to tease apart BM-derived versus
radioresistant stromal and endothelial cells within the
complex BM architecture (Figure 1). In the future, this
multicolor imaging approach will afford the opportunity to
interrogate the positioning, function, and interaction of
HSPCs and their progeny with surrounding stroma. Similarly,
methods used for single-cell tracking of BM-resident HSPCs
provide an opportunity to study howmature immune cells in
the BM interact with other BM-resident or circulating cells.
For example, central memory T cells have been shown to
engage circulating dendritic cells in the BM [12], and regu-
latory T cells (Tregs) have been observed to co-occupy with
HSPCs in the same BM niche, possibly providing an immune
sanctuary site for the persistence and survival of allogeneic
HSPCs in the BM [13]. Our imaging data also suggest that
under inﬂammatory conditions, BM-resident T cells migrate
at a markedly slower speed compared with T cells found in
an inﬂamed lymph node (Supplemental Movie 2). Additional
imaging studies have shed light onto how other cell typesmigrate to the BM niche, including circulating leukemic
cells, which use specialized BM endothelium to enter the BM
in an E-selectine and stromal cell derived factor 1 (SDF-1)e
dependent manner [14]. Future imaging experiments
promise to further highlight cellular and molecular deter-
minants responsible for observed stem cell and immune cell
behaviors within the live BM space.
Tracking hematopoietic-derived cells in the central nervous
system
In addition to studying cellular dynamics in the previ-
ously inaccessible BM cavity, investigators have increasing
interest in imaging immune responses in the central
nervous system (CNS). Questions regarding the role of
donor-derived versus host-derived immune cell compo-
nents in clinical settings such as BM transplantation (BMT)
and graft-versus-host disease (GVHD) can now be studied
using this high-resolution intravital imaging approach.
McGavern et al. [15] have led the ﬁeld in applying 2P-LSM
to study CNS immune response to an infectious challenge.
Other imaging studies have revealed immune cell behavior
during viral meningitis, including cytotoxic T cell activity
and cellular division on interaction with perivascular and
parenchymal APCs displaying cognate viral antigens, as
well as infection-associated vascular injury in the CNS.
Using BM chimeras, we were recently able to differentiate
donor BM-derived versus host tissue-derived APCs during
immune reactivity in the CNS (Figure 2 and Supplemental
Movie 3), opening the door for multicellular analyses of
CNS immunity in the future. In performing these sophisti-
cated intravital imaging experiments, McGavern et al. [15]
compared the craniotomy and skull-thinning procedures
commonly used for intravital CNS imaging experiments,
and found that the craniotomy approach resulted in
increased astrocyte and meningeal activation. In their
hands, the thin-skull technique resulted in less meningeal
irritation, because the procedure does not breach bone
integrity. However, because the integrity of the cranial BM
cavity is breached in the thin-skull approach, the procedure
carries a high risk of systemic inﬂammation, which may
lead to local and global changes in CNS tissues. Further-
more, we have found that with careful tissue handling,
microglia activation is not signiﬁcantly affected with either
technique, and that craniotomy can produce results that
Figure 2. Replacement of CNS APCs by BM-derived hematopoietic cells after BMT. A lethally irradiated C57BL/6 mouse was rescued with BM cells isolated from an
ubiquitin-CFP (white) donor mouse. (A) Static intravital 2P-LSM image captured through an implanted cranial observation window after LPS challenge showing
partial reconstitution of CNS APCs from BM-derived origin (white). (B) An xz view of the same imaged volume in (A). Dashed lines denote the arachnoid space,
delineating the meningeal layer (C) and the parenchymal layer (D). (E and F) Two zoomed-in views of (C). Note that both BM-derived (white and red) and
CNS-resident (red only) cell populations exhibit phagocytic capacity (intracellular red TRITC-dextran signals). Vessels are highlighted by TRITC-dextran (red). (Scale
bar: 50 mm.).
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shown). In summary, intravital CNS imaging techniques,
combined with cell lineageespeciﬁc ﬂuorescent reporter
mouse models, should enable detailed studies of immune
cellevesseleparenchyma communication in the settings of
BMT, infection, autoimmunity, and malignancy.
Summary
In vivo imaging is a rapidly advancing ﬁeld, with
increasing sophistication in imaging equipment, experi-
mental models, functional reporter reagents, and high-
throughput multiparameter data collection and analysis.
Indeed, the future of intravital imaging is dynamic and
bright. With proper appreciation of the promises and
potential pitfalls inherent in the2P-LSM technique [8],
investigators now have an exciting tool to probe biological
processes and mechanisms that were previously difﬁcult to
ascertain. Insights gained through 2P-LSM will be further
enhanced by interdisciplinary efforts in biology, physics,
mathematics, and computer sciences, which will be required
to examine fainter cells, smaller molecular structures, thicker
and denser tissues, and faster and more complex biochem-
ical events.
NEW INSIGHTS
Deﬁning the Molecular Phenotype of Virus-Speciﬁc T Cells
Immunodeﬁciency is a hallmark feature of the period
after BMT [16]. Although the degree of immunodeﬁciency
varies among individuals and is affected by numerous clin-
ical factors, a common feature of myeloablative preparative
regimens is lymphopenia. However, the numeric loss of
immune cells is not the sole factor explaining the suscepti-
bility of transplant recipients to infection. In the case of the
T cell compartment, both qualitative and quantitative
defects in T cell immunity occur. Although enumerating thefrequency of T cells is relatively straightforward, assessing
the qualitative, phenotypic aspects of Tcell immunity is more
complex. In this review we discuss recent advances in the
tools used by immunologists to identify phenotypes of
pathogen-speciﬁc T cells.
During a prototypical immune response to a viral path-
ogen, antigen-speciﬁc CD8þ T cells become activated,
proliferate, and gain effector functions. This initial burst of
proliferation yields a large number of effector cells, most of
which die during the contraction phase, leaving a smaller
population of antigen-speciﬁc cells that form the memory
pool. However, the population of antigen-speciﬁc CD8þ
T cells formed in response to a viral infection is highly
heterogeneous in terms of function and phenotype [17].
Thus, T lymphocytes speciﬁc for pathogens represent
a diverse collection of T cell states with a range of abilities to
exert control over infection. This diversity poses a particular
challenge for immunologists attempting to identify the
qualitative aspects of T cells correlated with protective
immunity [18].
Some of the most important advances in immunology
have come from studies of this heterogeneity in the T cell
compartment. Differential expression of surface antigens
ﬁrst identiﬁed the existence of helper T cell and cytotoxic T
cell lineages before an antigen encounter [19]. Subsequently,
isoforms of CD45 were used to differentiate T cells that had
experienced antigen stimulation from naive cells [20]. Sal-
lusto et al. [21] further divided antigen-experienced T cells
into those that express CCR7 and are found in lymphoid
tissues (central memory cells) and those that do not express
CCR7 and circulate in the periphery (effector memory cells).
Alongwith their phenotypic heterogeneity, T cells are also
functionally heterogeneous. Landmark studies by Mosmann
et al. [22] identiﬁed T helper cell (Th) Th1 and Th2 lineages in
the CD4 T cell compartment and paved the way for
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CD4 T cell lineages known today [23]. A high frequency of
Th1-type CD4 cells that secrete several cytokines simulta-
neously is characteristic of T cell responses that confer
immunity in some settings. The immunologic beneﬁts of this
trait, known as polyfunctionality, have subsequently been
conﬁrmed in HIV infection and vaccination [24,25], but its
usefulness as a marker of immunocompetence in allogeneic
BMT recipients is unclear.
The discovery of MHC tetramers provided a critical tool
with which to dissect the heterogeneity of the pool of
antigen-speciﬁc CD8þ T cells in humans [26]. Tetramer
staining allows antigen-speciﬁc T cells to be identiﬁed and
isolated independent of their surface phenotype. However,
although antigen-speciﬁc T cells can be assayed by cos-
taining with antibodies speciﬁc for many differentiation
markers, there is a limit to the number of labeled antibodies
that can be used to costain a population of cells, given the
overlap of excitation and emission spectra from closely
related ﬂuorochromes [27]. Because of this, it has become
difﬁcult to probe the phenotypic and functional complexity
of the T cell compartment beyond the existing states already
known.
Recent developments in ﬂow cytometry technology have
partially overcome this obstacle, however. The diversity of
the CD8 T cell compartment in humans has been studied
with a novel ﬂow cytometry technique based on single-cell
mass spectrometry known as cytometry by time-of-ﬂight
[28]. This platform allows resolution of many more anti-
body species (potentially hundreds), because there is
essentially no overlap in the mass:charge ratio of the
isotopes used to label the antibodies, unlike the emission
spectra of ﬂuorochromes. This technique has been used to
proﬁle the heterogeneity in the T cell compartment, and has
suggested that this phenotypic heterogeneity is even greater
than that already known. One important application of this
approach is in studying the recovery of phenotypic hetero-
geneity after BMT, much as previous studies have done with
TCR diversity.
In addition to probing the heterogeneity in the T cell
compartment using ﬂow cytometry, advances in nanoﬂuidics
enable examination of the functional diversity of a T cell
population [25]. In this approach, the functional state of
individual cells at a particular moment in time is studied by
placing individual live cells in nanowells and sampling the
cytokine content of the medium in each well repetitively
after T cell stimulation. Studies have shown that poly-
functionality does not appear to be the preserve of a partic-
ular subset of the cells, but rather is a transient characteristic
of many different cells that have produced and will produce
only a single cytokine.
A third approach to deﬁning the phenotypic features of
antigen-speciﬁc T cells involves analysis by genome-wide
gene expression proﬁling to create broad molecular pheno-
types [29,30]. We have studied gene expression proﬁles of
HIV-speciﬁc T cells from infected individuals with chroni-
cally elevated viral load in the absence of antiretroviral
therapy (progressors) and compared them with those of
individuals with spontaneous control of viral replication
(controllers) [30]. We found that the global pattern of gene
expression in HIV-speciﬁc T cells from progressors was very
similar to that seen in mouse lymphocyte choriomeningi-
tisespeciﬁc T cells responding to chronic versus acute viral
infection. Moreover, analysis of the genes that distinguish
between exhausted CD8þ T cells and their more functionalcounterparts identiﬁed a new role for the transcription factor
BATF in suppressing proliferation and cytokine secretion,
possibly by modulating AP-1 target genes.
As higher-powered techniques to assay the phenotype of
T cells are becoming available, several challenges have
emerged. These include the difﬁculty in distinguishing true
heritable differentiation states from transient activation
phenotypes, and the challenge of isolating sufﬁcient
numbers of increasingly rare subpopulations of T cells to
allow them to be studied. Finally, linking new T cell pheno-
types to their ability to confer immunologic protection to
individuals after BMT becomes more difﬁcult as candidate
phenotypes multiply.
NEW MODELS
Insights into the Immunology of Transplantation
Tolerance Using a Nonhuman Primate Model
In the previous sections we described novel strategies to
interrogate the immune response using both single-cell and
systems biology approaches. The increasing sensitivity and
ﬂexibility of these techniques has enabled the interrogation
of increasingly complex immunologic systems at a level of
detail not previously feasible. These advances are facilitating
a more detailed understanding of the biology of the immune
response in murine models and in patients, as well as in
novel transplant models, including those involving clinically
relevant nonhuman primates (NHPs). Toward this end, our
group and others have now developed NHP models able to
incorporate the genetic, ﬂow cytometry, and gene expression
tools traditionally available only for in vitro and murine
studies, such that the mechanisms controlling alloimmunity
can be discerned in this complex but highly translational
species.
Although historically NHP models have been rarely used
to study allogeneic BMT, in the ﬁeld of solid organ trans-
plantation, NHP models have long been identiﬁed as critical
to the most rapid introduction of new therapeutics into
clinical practice [31]. However, until very recently, trans-
plantation studies using NHPs have been severely limited by
poor knowledge of the NHP MHC. Indeed, until the advances
of the last 5 years, NHP transplantation studies were usually
performed with minimal or no information on animal
pedigree or MHC genetics. Given the critical impact of both
MHC and minor histocompatibility antigen disparity on BMT
outcomes, this severely limited the utility of NHP models of
BMT. However, 2 recent technical advances have funda-
mentally improved the ability to perform MHC typing in
macaques [32]: the application of DNA microsatellite-based
typing to rhesus pedigree analysis and MHC typing [33],
and the application of massively parallel pyrosequencing to
allele-speciﬁc MHC typing [34]. These technical advances
have allowed the creation of directed breeding colonies of
rhesus macaques inwhich the pedigree andMHC disparity in
all animals is known. Our group has used this resource to
develop the ﬁrst MHC-deﬁned models of both rejection and
GVHD in NHPs [32].
We have used both in vitro and in vivo analysis of allor-
eactivity to study the mechanisms controlling transplant
rejection and GVHD using the new NHP models. Central to
the in vitro studies was the ﬂow cytometric mixed lympho-
cyte reaction (MLR), which is capable of distinguishing the
degree of alloproliferation before and after transplantation,
as well as identifying the detailed phenotype of the allo-
proliferating cells (Figure 3). In this assay, peripheral blood
mononuclear cells (PBMCs) from transplant recipients are
Figure 3. CFSE MLR to measure alloreactivity. (A) Experimental schema for the CFSE MLR assay. To perform a CFSE MLR assay, PBMCs are puriﬁed and labeled with
CFSE as described previously [36]. The CFSE-labeled “responder” PBMCS are then mixed in culture with unlabeled “stimulator” PBMCs. As the T cells in the CFSE-
labeled responder population proliferate in response to the allostimulus, the CFSE in each successive division decreases owing to dilution. Thus, proliferation can
be measured by the decrease in CFSE ﬂuorescence, and T cell alloproliferation can be calculated by determining the proportion of cells demonstrating reduced CFSE
labeling. (B) T cells proliferating in response to alloantigens exhibit a CD2High/CD95þmemory phenotype. In the example shown here, CFSE-labeled responder PBMCs
were allostimulated with MHC-disparate stimulator PBMCs for 5 days. Cells were stained with an antibody cocktail consisting of anti-CD2, -CD3, -CD4, -CD8, -CD28,
and -CD95 antibodies, and data were acquired on an LSR II ﬂow cytometer (BD Biosciences, San Jose CA) and then analyzed with BD FACSDiva Software (BD
Biosciences, San Jose CA). Alloproliferation of T cells over the course of the assay was followed by CFSE dilution, and the expression of CD2 and CD95 was measured on
the proliferating cells.
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ﬂuorescein succinimidyl ester (CFSE). These cells are then
mixed in vitro with either donor PBMCs (to study rejection)
or cryopreserved pretransplantation recipient PBMCs (to
study GVHD), and the degree of alloreactivity is inferred from
the amount of proliferation measured in vitro (Figure 3A)[35]. These studies conﬁrmed that alloactivation in NHPs is
directly related to the degree of MHC disparity [35], and that
cells proliferating in response to alloantigens exhibit a CD2þ/
CD95þ memory phenotype (Figure 3B). CFSE MLR has been
subsequently used to predict the onset of rejection in an NHP
model of reduced-intensity conditioning and HSCT, in which
Figure 4. Tandem MLR to study the alloreactivity of effector T cells and Tregs in the same ﬂow cytometric reaction. Both CD4þ Tregs and T effectors were individually
stained with the proliferation marker CellTrace Violet (CTV), and then added to responder PBMCs stained with CFSE. Cultures were allostimulated with unlabeled
PBMCs for 5 days and then stained for CD3, CD4, and CD8. (A) Control MLR, with CFSE-labeled responders demonstrating no proliferation in the absence of stimulator
PBMCs. (B) Control MLR, with CTV-labeled Tregs demonstrating no proliferation in the absence of stimulator PBMCs. (C) MLR showing signiﬁcant alloproliferation of
both CFSE-labeled responder T cells and CTV-labeled effector T cells. (D) Ability of Tregs to inhibit the alloproliferation of CFSE-labeled responder cells (compare the
CFSE proliferation in D and C) while simultaneously undergoing alloproliferation themselves (compare the CTV proliferation in D and B).
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rejected by recipient T cells that are resistant to tolerance-
induction strategies [35]. We have recently reﬁned the allo-
proliferation assay and developed a “tandem MLR” in which
the alloreactivity of both effector T cells (labeled with CFSE)
and of ex vivo expanded Tregs labeled with a second track-
able dye (Cell-Trace Violet; Invitrogen, Carlsbad, CA) can be
determined in the same ﬂow cytometry experiment
(Figure 4) [36]. Through this dual-label approach, the impactFigure 5. Phenotyping Panel for Multipaof both positive and negative signals (and their reciprocal
interactions with both APCs and with one another) can be
sensitively measured in vitro.
In addition to in vitro assays of alloreactivity, our group
and others have used multiparameter ﬂow cytometry anal-
ysis to identify in vivomarkers of both rejection and GVHD in
NHPs. We have developed a series of ﬂow cytometry panels
(Figure 5) that allow us to sensitively query the peripheral
blood, BM, and lymph nodes longitudinally and the spleen,rameter Flow Cytometry in NHPs.
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of phenotypic and functional markers. The majority of the
antibodies used in these panels are highly cross-reactive
with human targets and thus also can be used to build
similar panels to analyze clinical trial samples longitudinally.
The cross-reactivity of the analytic reagents used for post-
transplantation immune monitoring represents a key
strength of the NHP studies, in that direct comparisons can
be made between immune analysis in NHPs and in patients.
Indeed, the multiparameter ﬂow cytometry (MFC) analysis
that we and others have performed in primates has led to
several observations that are now being tested in clinical
trials. The ﬁrst observation concerns the expansion of
memory phenotype cells that occurs before rejection of both
BM and solid organ allografts [35,37]. In NHPs, the expansion
of CD95 (Fas)þ/CD28þ central memory (CD4þ) and CD95þ/
CD28- effector memory (CD8þ) cells was strongly correlated
with impending rejection. This linkage betweenmemory cell
expansion and rejection is now being studied in clinical trials
of both solid organ transplantation and HSCT. The memory
phenotype T cells that were implicated in rejection in NHPs
also demonstrate increased expression of the adhesion
molecules CD2 and LFA-1 [38,39]. This observation has led
to the development of monitoring strategies for both
CD2 and LFA-1 expression (to test their predictive power for
the risk of alloactivation), as well as several intervention
trials targeting both CD2 and LFA-1 to prolong allograft
acceptance.
Along with using MFC to monitor and predict transplant
rejection, our group also has developed a rhesus macaque
model of GVHD in which alloactivation is measured through
a series of cell-based and serum-based multiplex assays [40].
Studies using the NHP GVHD model have established the
capability of MFC to monitor CD4þ and CD8þ T cell prolifer-
ation (using Ki-67), as well as the acquisition of markers of
memory (CD45RO, CCR7, CD95, CD28, CD2), activation
(CD38, HLA-DR, BCl-2, perforin, granzyme), and regulation
(FoxP3, CD25 in CD127- CD4þ cells) during GVHD or
its prevention with both standard-of-care and novel thera-
pies. This work identiﬁed the expression of both Ki-67
and granzyme B on peripheral blood CD8þ and CD4þ
T cells as sensitive markers of both GVHD (Ki-67high, gran-
zyme Bhigh) and its prevention (Ki-67low, granzyme Blow),
suggesting a novel approach to GVHD diagnosis and moni-
toring in the blood, which is currently under clinical
validation.
One of the key advantages of using the NHPmodel is that,
unlike other preclinical models, most of the novel biological
therapies currently being developed for patients are cross-
reactive with NHP targets and thus can undergo efﬁcient
preclinical efﬁcacy evaluation in NHPs. Our ﬁrst proof of
concept of this close link between NHP models and the clinic
was found with the costimulation blockade agent CTLA4-Ig
(abatacept). Our NHP studies supported the efﬁcacy of an
abatacept-containing regimen for the prevention of acute
GVHD. These results rapidly led to a ﬁrst-in-disease trial of
abatacept for GVHD prevention (ClinicalTrials.gov; NCT
01012492). This pilot study has shown encouraging phar-
macokinetic, biological, and clinical results and has led to the
initiation of a multicenter randomized Phase II study of
abatacept for GVHD prevention.
The development of detailed, multiplexed analysis tools
has transformed our ability to explore the mechanisms
controlling alloreactivity in both simple and complex
preclinical models. These technical advances have greatlyexpanded our ability to use the clinically relevant NHPmodel
to understand 2 of the most critical complications of BMT:
rejection and GVHD. These studies are able to offer new
mechanistic insights into the cause and control of these
posttransplantation complications, as well as provide key
preclinical data to rapidly translate new diagnostic and
therapeutic modalities to the clinic.CONCLUSION
Dynamic cellular imaging is a rapidly advancing ﬁeld.
Armed with increasingly sophisticated imaging equipment,
along with a proper appreciation of the promises and
potential pitfalls inherent to individual techniques and of the
new challenges that will inevitably emerge, investigators
now have an exciting opportunity to fully interrogate bio-
logical processes and mechanisms that were previously
difﬁcult to fully ascertain. Visualization and molecular char-
acterization of interactions involving a spectrum of immune
cells, ranging from undifferentiated blood stem cell progen-
itors to terminally differentiated central and effector
memory cells, is now possible at a level of detail not previ-
ously realized. Application of these techniques in relevant
mouse, NHP, and human systems is yielding new perspec-
tives with respect to how, where, and when immune cells
interact in vivo during inﬂammation, infection, and alloim-
munity and promises to adjust the lens through which the
next generation of immunologic advances will be observed,
appreciated, and enjoyed.ACKNOWLEDGMENTS
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